We are analyzing https://link.springer.com/article/10.1186/s40425-015-0078-9.

Title:
Pembrolizumab | Journal for ImmunoTherapy of Cancer
Description:
The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types. Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAF V600 mutation positive, a BRAF inhibitor. Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. There remain a number of pivotal trials in progress to further evaluate the optimal use of pembrolizumab alone and in combination for melanoma, NSCLC, and other tumor types. In this article, we review the efficacy and toxicity profile of pembrolizumab and evaluate its future development.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

patients, pembrolizumab, mgkg, pdl, response, melanoma, keynote, cancer, ipilimumab, treatment, tumor, months, article, orr, google, scholar, pubmed, pfs, data, median, expression, analysis, treated, nct, tumors, aes, cas, antibody, study, group, disease, phase, advanced, cell, combination, cells, doses, grade, weeks, staining, death, followup, receptor, antipd, lung, nsclc, safety, date, recist, trial,

Topics {✒️}

anti-programmed-death-receptor-1 treatment anti-pd-1/pd-l1 agent anti-pd-l1 antibody mpdl3280a pd-1 receptor-deficient mice small-cell lung cancer g4-kappa monoclonal antibody anti-pd-1 monoclonal antibody itim motif-carrying immunoreceptor programmed cell death infiltrating pd-1-expressing lymphocytes anti-pd-l1 antibody pd-1-deficient mice showed inflammation-induced cytokines produced pegylated interferon alpha-2b pd-1/pd-l1 axis define pd-l1 positivity pd-l1-negative tumors negative pd-l1 tumors interestingly pd-l1 expression immune-related response criteria pd-l1–positive tumors pd-l1-positive tumors pd-l1-positive tumors [36] article download pdf pd-1/pd-l1 inhibitors targeted therapy pd-l1-positive advanced anti-pd-l1 agents ��50 % pd-l1-tumor positivity tumor-infiltrating immune cells high pd-l1 expression treatment-related adverse events pd-l1 blockade independent central review antigen-specific immune response human dose-finding cohort tumor pd-l1 expression pd-1 immunoinhibitory receptor pd-l1 inhibitors bms-936559 peter kang & scot ebbinghaus receive pembrolizumab 2 mg/kg 1 treatment-related death checkpoint inhibitor lag-3 open access license google scholar anti-pd-1 antibody lung cancer treated 4-1bb ligand inhibitor privacy choices/manage cookies pd-l1 antibody

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Pembrolizumab
         description:The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types. Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAF V600 mutation positive, a BRAF inhibitor. Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. There remain a number of pivotal trials in progress to further evaluate the optimal use of pembrolizumab alone and in combination for melanoma, NSCLC, and other tumor types. In this article, we review the efficacy and toxicity profile of pembrolizumab and evaluate its future development.
         datePublished:2015-08-18T00:00:00Z
         dateModified:2015-08-18T00:00:00Z
         pageStart:1
         pageEnd:13
         license:https://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40425-015-0078-9
         keywords:
            Immune checkpoint blockade
            Melanoma
            Lung cancer
            Pembrolizumab
            Programmed death receptor 1
            Programmed death receptor ligand 1
            Oncology
            Immunology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0078-9/MediaObjects/40425_2015_78_Fig1_HTML.gif
         isPartOf:
            name:Journal for ImmunoTherapy of Cancer
            issn:
               2051-1426
            volumeNumber:3
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Leila Khoja
               affiliation:
                     name:Princess Margaret Cancer Centre
                     address:
                        name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marcus O. Butler
               affiliation:
                     name:Princess Margaret Cancer Centre
                     address:
                        name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Peter Kang
               affiliation:
                     name:Merck & Co., Inc.
                     address:
                        name:Merck & Co., Inc., Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Scot Ebbinghaus
               affiliation:
                     name:Merck & Co., Inc.
                     address:
                        name:Merck & Co., Inc., Kenilworth, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anthony M. Joshua
               affiliation:
                     name:Princess Margaret Cancer Centre
                     address:
                        name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pembrolizumab
      description:The development of the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and its approval in 2011 for the treatment of metastatic melanoma has heralded a new era in immuno-oncology. Subsequently, novel agents against the programmed death receptor 1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis have shown significant activity in melanoma and a variety of other tumor types. Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAF V600 mutation positive, a BRAF inhibitor. Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. There remain a number of pivotal trials in progress to further evaluate the optimal use of pembrolizumab alone and in combination for melanoma, NSCLC, and other tumor types. In this article, we review the efficacy and toxicity profile of pembrolizumab and evaluate its future development.
      datePublished:2015-08-18T00:00:00Z
      dateModified:2015-08-18T00:00:00Z
      pageStart:1
      pageEnd:13
      license:https://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40425-015-0078-9
      keywords:
         Immune checkpoint blockade
         Melanoma
         Lung cancer
         Pembrolizumab
         Programmed death receptor 1
         Programmed death receptor ligand 1
         Oncology
         Immunology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-015-0078-9/MediaObjects/40425_2015_78_Fig1_HTML.gif
      isPartOf:
         name:Journal for ImmunoTherapy of Cancer
         issn:
            2051-1426
         volumeNumber:3
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Leila Khoja
            affiliation:
                  name:Princess Margaret Cancer Centre
                  address:
                     name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marcus O. Butler
            affiliation:
                  name:Princess Margaret Cancer Centre
                  address:
                     name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Peter Kang
            affiliation:
                  name:Merck & Co., Inc.
                  address:
                     name:Merck & Co., Inc., Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Scot Ebbinghaus
            affiliation:
                  name:Merck & Co., Inc.
                  address:
                     name:Merck & Co., Inc., Kenilworth, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anthony M. Joshua
            affiliation:
                  name:Princess Margaret Cancer Centre
                  address:
                     name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal for ImmunoTherapy of Cancer
      issn:
         2051-1426
      volumeNumber:3
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Princess Margaret Cancer Centre
      address:
         name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
         type:PostalAddress
      name:Princess Margaret Cancer Centre
      address:
         name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
         type:PostalAddress
      name:Merck & Co., Inc.
      address:
         name:Merck & Co., Inc., Kenilworth, USA
         type:PostalAddress
      name:Merck & Co., Inc.
      address:
         name:Merck & Co., Inc., Kenilworth, USA
         type:PostalAddress
      name:Princess Margaret Cancer Centre
      address:
         name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Leila Khoja
      affiliation:
            name:Princess Margaret Cancer Centre
            address:
               name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Marcus O. Butler
      affiliation:
            name:Princess Margaret Cancer Centre
            address:
               name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:S. Peter Kang
      affiliation:
            name:Merck & Co., Inc.
            address:
               name:Merck & Co., Inc., Kenilworth, USA
               type:PostalAddress
            type:Organization
      name:Scot Ebbinghaus
      affiliation:
            name:Merck & Co., Inc.
            address:
               name:Merck & Co., Inc., Kenilworth, USA
               type:PostalAddress
            type:Organization
      name:Anthony M. Joshua
      affiliation:
            name:Princess Margaret Cancer Centre
            address:
               name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
      name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada
      name:Merck & Co., Inc., Kenilworth, USA
      name:Merck & Co., Inc., Kenilworth, USA
      name:Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada

External Links {🔗}(119)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.47s.

LINK . SPRINGER . COM {}